Showing 611-620 of 7438 results for "".
Fillers for the Décolletage Area
https://practicaldermatology.com/topics/practice-management/fillers-for-the-dcolletage-area/21113/Fillers offer patients an alternative to device-based interventions for chest rejuvenation.o, MDPanel Supports ATX-101; Melanoma Metastasis Test
https://practicaldermatology.com/topics/practice-management/dermwiretv-panel-supports-atx-101-melanoma-metastasis-test/18959/An FDA Advisory Panel Backs Kythera's ATX-101 for (Submental Fullness) or Double Chin, and a new genetic analysis may enhance SLN Biopsy findings to identify melanoma metastasis.Plus, Dan Siegel, MD, Darrell Rigel, MD, and Neal Bhatia, MD discuss the AAD's proposed dues increase and @NewDermMD launc“Natural” Remedies for Eczema: Evidence for the Alternative?
https://practicaldermatology.com/topics/general-topics/natural-remedies-for-eczema-evidence-for-the-alternative/22936/Limited data suggest the possibility that some natural agents may be particularly useful in the treatment of atopic dermatitis.FDA Approves Eli Lilly’s AD Drug Ebglyss (Lebrikizumab)
https://practicaldermatology.com/series/dermwire-tv/fda-approves-eli-lillys-ad-drug-ebglyss-lebrikizumab/28645/In this week's DermwireTV, Andrew F. Alexis, MD, Professor of Clinical Dermatology at Weill Cornell Medical College, discusses the newly approved AD drug lebrikizumab; LEO Pharma announces two major regulatory milestones for its chronic hand eczema (CHE) treatment; and the CMO of Arcutis BioteherapuJournal Club: What's New in Pathogenesis and Treatment of Atopic Dermatitis
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/journal-club-whats-new-in-pathogenesis-and-treatment-of-atopic-dermatitis/26247/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, talks with Jason E. Hawkes, MD, a dermatologist practicing in the Sacramento area, and a member of the Practical Dermatology Editorial Board, about the latest research on the pathogenesis of and treatment targets for atopic dermatitis (AD).Atopic Dermatitis and Psoriasis: Treatments, Considerations, and What’s Coming
https://practicaldermatology.com/topics/atopic-dermatitis/atopic-dermatitis-and-psoriasis-treatments-considerations-and-whats-coming/24038/Atopic dermatitis (AD) and plaque psoriasis (PsO) are two of the most common cutaneous conditions we treat in dermatology. While these chronic inflammatory disorders have similarities, regarding chronic skin disease burden and impact on quality of life, they may diverge when considering clinical preFor Now, the No Surprises Act Applies to All Providers
https://practicaldermatology.com/topics/practice-management/for-now-the-no-surprises-act-applies-to-all-providers/23780/It seems that dermatologists and others providing aesthetic services must comply with new legislation.DermWireTV: AbbVie's Science of Skin Panel, Monkeypox Warning, Recommendations on Skin Cancer Detection Devices, UV Filters and Aquatic Life
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-abbvies-science-of-skin-panel-monkeypox-warning-recommendations-on-skin-cancer-detection-devices-uv-filters-and-aquatic-life/20131/“The Science of Skin: United Beyond the Surface” program sponsored by AbbVie brings together leading dermatologists and patients or caregivers of patients with dermatologic disease to explore the burden of skin diseases on diverse populations and the need for optimized treatment approaches. Seemal DThe ACTS Program: Adding Testing to Your Defense Against COVID-19
https://practicaldermatology.com/issues/supplements/the-acts-program-adding-testing-to-your-defense-against-covid-19/23419/Adopting a simple testing and safety platform for personal protective equipment and sterilization protocols adds a layer of protection for patients and office staff.Are You Taking Advantage of Two Everyday Tax-Favored Assets?
https://practicaldermatology.com/topics/practice-management/are-you-taking-advantage-of-two-everyday-tax-favored-assets/23229/Are you taking advantage of two everyday tax-favored assets?